MINNEAPOLIS, Feb. 26 /PRNewswire-FirstCall/ -- ProUroCare Medical, Inc. (OCT Bulletin Board: PUMD, PUMDU, PUMDW), a provider of proprietary medical imaging products, indicates that the Food and Drug Administration has informed the industry that the processing of 510(k) applications, which includes the ProUroScan(TM) prostate imaging system, has been delayed because of the inclement weather in February that impacted the Washington, D.C. area. It is anticipated that the delay will not be significant.
About ProUroCare Medical, Inc.
ProUroCare Medical, Inc. is a publicly traded company engaged in the business of creating innovative medical imaging products. The company's current focus is the ProUroScan prostate imaging system, which is now in clinical trials for the mapping of prostate abnormalities detected by DRE. Based in Minneapolis, Minn., ProUroCare is traded on the OTCBB market.
Safe Harbor Statement
This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of ProUroCare's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause ProUroCare's results to differ materially from those expressed or implied by such forward-looking statements are detailed from time to time in ProUroCare's filings with the Securities and Exchange Commission including its most recently filed Form 10-K and Form 10-Q.
ProUroCare Medical, Inc.
CONTACT: Rick Carlson, Chief Executive Officer of ProUroCare Medical,
Inc., +1-952-476-9093, rcarlson@prourocare.com; or Laura Aumann of Kohnstamm
Communications, +1-651-228-9141, laura@kohnstamm.com, for ProUroCare Medical,
Inc.
